 |
Gusperimus |
|---|---|
| Trade Name | Spanidin |
| Orphan Indication | Acute renal graft rejection episodes |
| USA Market Approval | USA |
| USA Designation Date | 1996-06-27 00:00:00 |
| Sponsor | Bristol-Myers Squibb Pharmaceutical Research Institute;5 Research Parkway, P.O. Box 5100;Wallingford, Connecticut, 06492 |
